John Grous

6.9k total citations · 4 hit papers
23 papers, 5.1k citations indexed

About

John Grous is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, John Grous has authored 23 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in John Grous's work include Cancer Research and Treatments (6 papers), Neutropenia and Cancer Infections (6 papers) and Lung Cancer Treatments and Mutations (6 papers). John Grous is often cited by papers focused on Cancer Research and Treatments (6 papers), Neutropenia and Cancer Infections (6 papers) and Lung Cancer Treatments and Mutations (6 papers). John Grous collaborates with scholars based in United States, Netherlands and Germany. John Grous's co-authors include Michael Wolf, Roy S. Herbst, Giuseppe Giaccone, David H. Johnson, Steven D. Averbuch, Vincent A. Miller, Ronald B. Natale, Joan H. Schiller, Christian Manegold and Rafael Rosell and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

John Grous

23 papers receiving 4.9k citations

Hit Papers

Gefitinib in Combination With Gemcitabine and Cisp... 1988 2026 2000 2013 2004 2004 1991 1988 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
    2004 1.4k citations Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology profile →
  2. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →
  3. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
    1991 1.1k citations Jeffrey Crawford, Howard Ozer et al. New England Journal of Medicine profile →
  4. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
    1988 763 citations Janice Gabrilove, Ann A. Jakubowski et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Grous United States 12 4.1k 2.6k 966 686 680 23 5.1k
Jan Walewski Poland 31 4.2k 1.0× 736 0.3× 710 0.7× 493 0.7× 518 0.8× 214 7.0k
Ronald G. Stoller United States 27 2.0k 0.5× 535 0.2× 920 1.0× 557 0.8× 568 0.8× 63 3.5k
Fredrick B. Hagemeister United States 52 4.3k 1.1× 1.2k 0.4× 791 0.8× 259 0.4× 925 1.4× 257 8.5k
Frank Dunphy United States 25 2.4k 0.6× 2.1k 0.8× 735 0.8× 141 0.2× 391 0.6× 65 3.6k
Alan Yagoda United States 34 2.3k 0.6× 1.9k 0.7× 869 0.9× 342 0.5× 496 0.7× 104 6.1k
Scott I. Bearman United States 28 1.7k 0.4× 1.5k 0.6× 1.1k 1.1× 255 0.4× 2.7k 4.0× 59 5.2k
Svetislava J. Vukelja United States 30 4.2k 1.0× 954 0.4× 697 0.7× 397 0.6× 246 0.4× 83 5.2k
W M Crist United States 41 2.0k 0.5× 1.9k 0.7× 1.4k 1.5× 303 0.4× 1.9k 2.7× 75 6.1k
Bruce D. Cheson United States 37 3.7k 0.9× 1.1k 0.4× 1.9k 1.9× 168 0.2× 2.9k 4.2× 130 9.6k
Wayne Rackoff United States 19 1.0k 0.3× 945 0.4× 766 0.8× 172 0.3× 823 1.2× 35 2.9k

Countries citing papers authored by John Grous

Since Specialization
Citations

This map shows the geographic impact of John Grous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Grous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Grous more than expected).

Fields of papers citing papers by John Grous

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Grous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Grous. The network helps show where John Grous may publish in the future.

Co-authorship network of co-authors of John Grous

This figure shows the co-authorship network connecting the top 25 collaborators of John Grous. A scholar is included among the top collaborators of John Grous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Grous. John Grous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hassan, Raffit, Evan Alley, Hedy L. Kindler, et al.. (2015). Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). Journal for ImmunoTherapy of Cancer. 3(S2). 3 indexed citations
2.
3.
Hassan, Raffit, Scott Antonia, Evan Alley, et al.. (2015). Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 33(15_suppl). 7565–7565. 4 indexed citations
4.
Le, Dung T., Andrea Wang‐Gillam, Vincent J. Picozzi, et al.. (2014). A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. Journal of Clinical Oncology. 32(3_suppl). 177–177. 25 indexed citations
5.
Hassan, Raffit, Evan Alley, Hedy L. Kindler, et al.. (2014). Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 32(15_suppl). 7532–7532. 5 indexed citations
6.
Le, Dung T., Andrea Wang‐Gillam, Vincent J. Picozzi, et al.. (2013). Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 31(15_suppl). 4040–4040. 9 indexed citations
7.
Brockstedt, Dirk G., Dung T. Le, Raffit Hassan, et al.. (2013). Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors. Journal for ImmunoTherapy of Cancer. 1(S1). 5 indexed citations
8.
Grous, John, et al.. (2009). Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). Journal of Clinical Oncology. 27(15_suppl). 9627–9627. 3 indexed citations
9.
Grous, John, Charles H. Redfern, Daruka Mahadevan, & Joanne Schindler. (2006). GCS-100, a galectin-3 antagonist, in refractory solid tumors: A phase I study. Journal of Clinical Oncology. 24(18_suppl). 13023–13023. 16 indexed citations
10.
Giaccone, Giuseppe, Roy S. Herbst, Christian Manegold, et al.. (2004). Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. Journal of Clinical Oncology. 22(5). 777–784. 1388 indexed citations breakdown →
11.
12.
Bailey, Lisa, Karsten Schmidt, Niels Bindslev, et al.. (2004). Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. Journal of Clinical Oncology. 22(14_suppl). 7013–7013. 35 indexed citations
13.
Herbst, Roy S., Giuseppe Giaccone, Joan H. Schiller, et al.. (2004). Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal of Clinical Oncology. 22(5). 785–794. 1374 indexed citations breakdown →
14.
15.
Ozer, Howard, Ronald G. Stoller, David H. Johnson, et al.. (1994). Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. Clinical Infectious Diseases. 18(Supplement_2). S189–S196. 49 indexed citations
16.
Crawford, Jeffrey, Howard Ozer, Ronald G. Stoller, et al.. (1991). Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. New England Journal of Medicine. 325(3). 164–170. 1109 indexed citations breakdown →
17.
Pais, Vernon M., et al.. (1991). Adenocarcinoma of the Urachus Associated with Elevated Levels of CA 125. The Journal of Urology. 145(1). 140–141. 28 indexed citations
18.
Gabrilove, Janice, Ann A. Jakubowski, Howard I. Scher, et al.. (1989). Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium. The Journal of Urology. 141(2). 453–454. 11 indexed citations
19.
Gabrilove, Janice, Ann A. Jakubowski, Katie Fain, et al.. (1988). Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.. Journal of Clinical Investigation. 82(4). 1454–1461. 183 indexed citations
20.
Gabrilove, Janice, Ann A. Jakubowski, Howard I. Scher, et al.. (1988). Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium. New England Journal of Medicine. 318(22). 1414–1422. 763 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Walewski Breakdown of academic impact, for papers by Ronald G. Stoller Breakdown of academic impact, for papers by Fredrick B. Hagemeister Breakdown of academic impact, for papers by Frank Dunphy Breakdown of academic impact, for papers by Alan Yagoda Breakdown of academic impact, for papers by Scott I. Bearman Breakdown of academic impact, for papers by Svetislava J. Vukelja Breakdown of academic impact, for papers by W M Crist Breakdown of academic impact, for papers by Bruce D. Cheson Breakdown of academic impact, for papers by Wayne Rackoff
Rankless by CCL
2026